Posted by Michael Wonder on 24 Feb 2023
Merck and Ridgeback provide update on EU marketing authorisation application for Lagevrio (molnupiravir)
24 February 2023 - Merck and Ridgeback Biotherapeutics today announced that the CHMP of the EMA has recommended the refusal of the marketing authorisation for Lagevrio (molnupiravir) for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
